Setidegrasib results published in New England Journal of Medicine FORT MYERS, Fla., April 2, 2026 /PRNewswire/ -- Results of a Phase 1 clinical study conducted with participation from Florida Cancer ...

ORR 35.8% overall, 37.5% in second-/third-line, and 47.1% in light/nonsmokers, with median DOR not reached in key subsets.

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution ...

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be ...

Setidegrasib, an emerging targeted therapy, has shown promising efficacy in a phase I trial involving patients with ...

"There is a clear unmet need for therapies," researcher says ...

Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...

KRAS is one of the most commonly mutated genes in human cancers and it is found in more than 90% of pancreatic cancer tumors. Exactly how it spurs cancer growth, however, is poorly understood. That's ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...